Views & Analysis | Perspectives on pharma industry issues

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Digital

IQVIA Technologies sponsored podcast, with Updesh Dosanjh

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Articles

Medical devices: the future is emerging markets

Following our emerging markets focus, Jim Furniss provides thoughts on the opportunities and challenges for the device market. The healthcare industry has recognised for a number of years that there is a great untapped potential in emerging markets...

Articles

Are you ready for the new EU pharmacovigilance legislation c...

In part two of his two-part article, Graeme Ladds continues to explore the new EU pharmacovigilance legislation due to come into force in July 2012, looking at the introduction of social media and an outlook on the future. There are 16 guidance documents to accompany the new legislation and part two of this article further explores some of...

Articles

Media perspectives: Gill Cox

We speak with health expert and agony aunt, Gill Cox, for this month’s Media Perspectives interview, about women’s health, some of the craziest stories she’s reported on and the rise in social networking. Every month we gain an insight into the lives of those working within both the media and healthcare industries through our Media Perspectives series...

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology